Triathlon Tritanium Knee Outcomes Study

The success of the Triathlon Tritanium Knee will be determined by comparing the rate of absence of revision for aseptic loosening of the tibial baseplate at 2 years with the rates reported in the literature.

Study Overview

• Status: Terminated
• Conditions: Arthroplasty, Replacement, Knee
• Intervention / Treatment: Device: Triathlon Tritanium Knee; Device: Triathlon Knee

Detailed Description

Cases are to be enrolled at five to ten centers. The same center may be included in both arms. Conversely, a center may choose to participate in only a single arm. The enrollment goal is approximately 36 - 72 cases per center for Cohort 1 (cementless) and 15 - 30 cases per center for Cohort 2 (cemented) , and will vary dependent upon the number of participating centers. Although a goal is presented, there is no maximum limit to the number of cases that a center may enroll. In the event that a center far exceeds the enrollment goal, Stryker may ask the center to cease enrollment so as not to skew the data. All participating centers will comply with the federal regulations regarding patient informed consent and Institutional Review Board (IRB) or Ethics Committee (EC) approval. Non-compliance of a study center may result in termination of the center's participation in the study.

• Study Type: Interventional
• Enrollment (Actual): 680
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • OrthoArizona
    • Tucson, Arizona, United States, 85741
      • Tucson Orthopaedic Institute
  • Florida
    • Jacksonville, Florida, United States, 32204
      • Heekin Clinic
  • Louisiana
    • Lake Charles, Louisiana, United States, 70605
      • Imperial Health
  • Maryland
    • Baltimore, Maryland, United States, 21215
      • Sinai Hospital of Baltimore
  • Michigan
    • Ypsilanti, Michigan, United States, 48197
      • St. Joseph Mercy Health System
  • New Jersey
    • Egg Harbor Township, New Jersey, United States, 08234
      • Rothman Orthopaedic Institute
  • North Carolina
    • Asheville, North Carolina, United States, 28801
      • Mission Hospital Research Institute
    • Durham, North Carolina, United States, 27703
      • Duke University Medical Center
  • Pennsylvania
    • Danville, Pennsylvania, United States, 17821
      • Geisinger Orthopaedic Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved; study specific Informed Patient Consent Form.
2. Patient is a male or non-pregnant female age 18-75 years at time of study device implantation.
3. Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).
4. Patient is a candidate for primary cementless total knee replacement, including a resurfaced patella.
5. Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.

Exclusion Criteria:

1. Patient has a Body Mass Index (BMI) > 40.
2. Patient has a diagnosis of avascular necrosis or inflammatory arthritis.
3. Patient has an active or suspected latent infection in or about the affected knee joint at time of study device implantation.
4. Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.
5. Subject is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.
6. Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days).
7. Patient is diagnosed with lumbar radicular pain.
8. Patient has a known sensitivity to device materials.
9. Patient is a prisoner.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Triathlon Tritanium Knee; Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.	Device: Triathlon Tritanium Knee; Cementless
Active Comparator: Triathlon Knee; Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.	Device: Triathlon Knee; Cemented

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Knees With Cementless Application That Had Successful Primary Total Knee Replacement With the Triathlon Tritanium Total Knee System	Success is defined as freedom from Triathlon Tritanium Tibial Baseplate revision for aseptic loosening.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare Oxford Knee Score (OKS) Scores Between Both Groups	The OKS questionnaire consists of 12 questions that cover function and pain of the knee. Each question is scored from 0 to 4 (0 being the worst outcome and 4 being the best). The overall score is the sum of all items and can range from 0 to 48, with higher scores corresponding to better outcomes.	2 years
Implant Survivorship (Baseplate and Patella)	This secondary outcome measure is a statistical estimation on the number of cases at risk at 1-year, 3-years, 5-years and 7-years postoperative in the cementless cohort 1 only, per protocol. The final 10-year results were not done due to early study termination.	10 years
Compare 2011 Knee Society Score (KSS) Scores Between Both Groups	The 2011 Knee Society Score System is comprised of 4 distinct sub-scores: Objective, Functional, Patient Satisfaction and Expectations. The Objective and Functional sub-scores range from a potential minimum score of 0 to a maximum score of 100 points. The Patient Satisfaction sub-score ranges from a potential minimum score of 0 to a maximum score of 40 points. The Subject Expectations sub-score ranges from a potential minimum score of 0 to a maximum score of 15 points. Although the specific scores are not distinguished as "excellent," "good," "fair," or "poor," a higher value represents a better outcome.	2 years
Compare Short Form-12 (SF-12) Scores Between Both Groups	The SF-12 Health Survey is a 12-item patient quality-of-life questionnaire to measure general health and well-being. It is comprised of two distinct scores (physical and mental component score). They are both calculated on a scale ranging from 0 points to 100 points, with low values representing a poor health state and high values representing a good health state.	2 years

Collaborators and Investigators

• Sponsor: Stryker Orthopaedics
• Investigators: Principal Investigator: Edward Petrow, DO, Tucson Orthopaedic Institute; Principal Investigator: Alvin Ong, MD, Rothman Orthopaedic Institute; Principal Investigator: David Heekin, MD, Heekin Clinic; Principal Investigator: Kipling Sharpe, MD, OrthoArizona; Principal Investigator: Marcus Barnett, MD, Mission Hospital Research Institute; Principal Investigator: John Noble, MD, Imperial Health; Principal Investigator: Michael Masini, MD, St. Joseph Mercy Health System; Principal Investigator: Ronald Delanois, MD, Sinai Hospital of Baltimore; Principal Investigator: Thomas Bowen, MD, Geisinger Orthopaedic Institute; Principal Investigator: Samuel Wellman, MD, Duke University

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2014
• Primary Completion (Actual): April 5, 2018
• Study Completion (Actual): March 11, 2023

Study Registration Dates

• First Submitted: June 2, 2014
• First Submitted That Met QC Criteria: June 2, 2014
• First Posted (Estimated): June 4, 2014

Study Record Updates

• Last Update Posted (Actual): November 14, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 74

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No